| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1055-9965.EPI-07-0599 |
| P698 | PubMed publication ID | 18006910 |
| P50 | author | Anssi Auvinen | Q47337660 |
| P2093 | author name string | Teuvo L J Tammela | |
| Teemu J Murtola | |||
| Jorma Lahtela | |||
| P433 | issue | 11 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 2226-2232 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Cancer Epidemiology, Biomarkers & Prevention | Q326334 |
| P1476 | title | Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study | |
| P478 | volume | 16 |
| Q90589091 | A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer |
| Q92060712 | Anti-Androgen Abiraterone Acetate Improves the Therapeutic Efficacy of Statins on Castration-Resistant Prostate Cancer Cells |
| Q35775751 | Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. |
| Q36877126 | Association between plasma cholesterol and prostate cancer in the PSA era. |
| Q34418735 | Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort |
| Q37167232 | Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. |
| Q34415704 | Association of serum cholesterol and cholesterol-lowering drug use with serum sex steroid hormones in men in NHANES III. |
| Q24614649 | Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery |
| Q57307183 | Blood lipid levels and prostate cancer risk; a cohort study |
| Q57140725 | Chemoprevention of prostate cancer |
| Q34606617 | Chemoprevention of prostate cancer: what can be recommended to patients? |
| Q33732687 | Cholesterol and benign prostate disease |
| Q42079833 | Cholesterol and prostate cancer |
| Q39001029 | Cholesterol-induced activation of TRPM7 regulates cell proliferation, migration, and viability of human prostate cells. |
| Q37596358 | Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo |
| Q81407191 | Current awareness: pharmacoepidemiology and drug safety |
| Q38030598 | Dyslipidemia, statins and prostate cancer |
| Q36586161 | Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. |
| Q42982919 | Effect of Statins on Serum Prostate-specific Antigen Levels |
| Q39031198 | Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review. |
| Q43190182 | Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer |
| Q38728309 | Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model |
| Q42045919 | Ezetimibe is an inhibitor of tumor angiogenesis |
| Q43415543 | Genetic variants associated with predisposition to prostate cancer and potential clinical implications |
| Q39324750 | Identification of androgen-regulated genes in human prostate. |
| Q34141720 | Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors |
| Q37779059 | Impact of statin therapy on survival in epithelial ovarian cancer |
| Q35030507 | Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independence |
| Q35988999 | LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies. |
| Q38077536 | LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly. |
| Q57456267 | Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white men in the ARIC Study |
| Q38918249 | Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells |
| Q37547305 | Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer |
| Q33882778 | Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial |
| Q33769607 | Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol |
| Q51156222 | Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: a simulation study. |
| Q38242231 | Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression |
| Q42956899 | Nutrients and risk of prostate cancer |
| Q37794799 | Prevention Strategies in Prostate Cancer |
| Q91716441 | Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels |
| Q61145116 | Prostate Cancer: Is It a Battle Lost to Age? |
| Q53063710 | Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. |
| Q92234762 | Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications |
| Q38802230 | Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients? |
| Q37258845 | Rationale for statins in the chemoprevention of prostate cancer. |
| Q46892598 | Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients |
| Q37283766 | Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer |
| Q34158413 | Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. |
| Q36293122 | Serum lipid profiles: novel biomarkers predicting advanced prostate cancer in patients receiving radical prostatectomy. |
| Q36407365 | Serum total and HDL cholesterol and risk of prostate cancer |
| Q40495259 | Simvastatin blocks TGF-β1-induced epithelial-mesenchymal transition in human prostate cancer cells |
| Q41472414 | Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study |
| Q91884090 | Statin Use and the Risk of Prostate Cancer in Ischemic Heart Disease Patients in Taiwan |
| Q26738631 | Statin Use in Prostate Cancer: An Update |
| Q34003588 | Statin and NSAID use and prostate cancer risk |
| Q33922625 | Statin drug use is not associated with prostate cancer risk in men who are regularly screened |
| Q59336382 | Statin drugs to reduce breast cancer recurrence and mortality |
| Q34433564 | Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. |
| Q35282895 | Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database |
| Q34021312 | Statin use and cancer risk: a comprehensive review |
| Q35038889 | Statin use and fatal prostate cancer: a matched case-control study |
| Q85995735 | Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study |
| Q36953616 | Statin use and prostate cancer risk in a large population-based setting |
| Q44904629 | Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. |
| Q21133952 | Statin use and risk of prostate cancer: a meta-analysis of observational studies |
| Q36978974 | Statin use and risk of prostate cancer: results from a population-based epidemiologic study |
| Q38047044 | Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies |
| Q44560037 | Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies |
| Q87527196 | Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy |
| Q39828211 | Statin use is associated with improved prostate cancer survival: is it time for a clinical trial? |
| Q26777793 | Statins and cancers |
| Q36449867 | Statins and prostate cancer diagnosis and grade in a veterans population |
| Q37187362 | Statins and prostate cancer prevention: where we are now, and future directions. |
| Q27000727 | Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis |
| Q35264079 | Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins |
| Q39830389 | Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis |
| Q34976557 | The association between statin use and the diagnosis of prostate cancer in a population based cohort |
| Q34590302 | The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer |
| Q35137013 | The complex interplay between cholesterol and prostate malignancy |
| Q38800777 | The current evidence on statin use and prostate cancer prevention: are we there yet? |
| Q26822900 | The failure of cancer chemoprevention |
| Q34102004 | The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study |
| Q44840521 | The influence of statin medications on prostate-specific antigen levels |
| Q24604956 | The relationship between nutrition and prostate cancer: is more always better? |
| Q34328954 | The response of the prostate to circulating cholesterol: activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network |
| Q34127128 | The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction |
| Q34428524 | Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials |
Search more.